Middle East & Africa Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)
The Middle East & Africa Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US$ 1,064.3 million by 2031, up from US$ 270.8 million in 2024, with an estimated compound annual growth rate (CAGR) of 22.3% from 2025 to 2031.
Executive Summary and Market Analysis
The anti-obesity drugs market in the Middle East & Africa is divided into key regions including the UAE, Saudi Arabia, South Africa, and the broader Middle East & Africa. Factors such as increased suburbanization and lifestyle changes have led to a rise in the consumption of high-calorie processed foods and a decrease in physical activity, resulting in higher obesity rates. Additionally, there is a growing awareness of the health risks associated with obesity, such as diabetes, cardiovascular diseases, and certain cancers, which has spurred demand for medical treatments. Governments and health organizations are launching public health initiatives to combat obesity, further driving market growth. Enhanced access to healthcare, rising disposable incomes, and increased investment in healthcare infrastructure are also contributing to this expansion. Moreover, the presence of pharmaceutical companies offering innovative anti-obesity treatments, particularly GLP-1 receptor agonists, is on the rise. As cultural attitudes evolve and medical tourism becomes more prevalent, especially in countries like the UAE and South Africa, the anti-obesity drug market is expected to continue its upward trajectory.
Strategic Insights
Market Segmentation Analysis
Obesity is influenced by genetic, environmental, and lifestyle factors. Recent advancements indicate that individuals respond differently to anti-obesity medications based on their genetic profiles, metabolic rates, gut microbiota, and existing health conditions. This variability means that a medication effective for one patient may not work for another. Precision medicine is emerging in obesity treatment, utilizing pharmacogenomic testing and detailed patient profiling to identify the most effective drug or combination of drugs for each individual. Companies are developing diagnostic tools to analyze genetic markers related to obesity and drug metabolism, aiding clinicians in predicting patient responses to various treatments. The expanding pipeline of anti-obesity drugs targeting different mechanisms allows for tailored therapies that align with individual patient needs. For instance, if a patient does not respond well to a GLP-1 agonist, a physician may consider switching to or combining it with another agent targeting a different pathway.
Pharmacogenomic companies like Acosta and Phenomix are providing tests that support personalized obesity treatment, a trend expected to accelerate as more data and drugs become available. This shift towards individualized treatment regimens is anticipated to enhance the effectiveness, cost-efficiency, and acceptance of anti-obesity pharmacotherapy among patients and healthcare providers. In March 2025, VIVUS LLC launched QSYMIA® (phentermine and topiramate extended-release capsules) in the UAE, marking a significant step in addressing the region's rising obesity rates, projected to affect over 7.5 million people by 2035.
Country Insights
The market is further segmented by country, with Saudi Arabia holding the largest share in 2024. The prevalence of overweight and obesity in Saudi Arabia has nearly doubled over the past fifty years, with over half the population classified as overweight and more than 20% as obese. The economic burden of obesity management in the country is estimated at US$ 6.4 billion, underscoring the urgent need for effective interventions. The Saudi government has implemented various policies under its Vision 2030 plan to promote a healthier population.
In April 2025, Novo Nordisk signed a Memorandum of Understanding with Lifera to localize the manufacturing of semaglutide-based GLP-1 treatments in Saudi Arabia, enhancing the country's healthcare infrastructure. This agreement aims to launch Wegovy in Saudi Arabia, making it accessible to patients in both public and private sectors, reflecting the country's commitment to tackling obesity.
Company Profiles
Key players in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence.
Executive Summary and Market Analysis
The anti-obesity drugs market in the Middle East & Africa is divided into key regions including the UAE, Saudi Arabia, South Africa, and the broader Middle East & Africa. Factors such as increased suburbanization and lifestyle changes have led to a rise in the consumption of high-calorie processed foods and a decrease in physical activity, resulting in higher obesity rates. Additionally, there is a growing awareness of the health risks associated with obesity, such as diabetes, cardiovascular diseases, and certain cancers, which has spurred demand for medical treatments. Governments and health organizations are launching public health initiatives to combat obesity, further driving market growth. Enhanced access to healthcare, rising disposable incomes, and increased investment in healthcare infrastructure are also contributing to this expansion. Moreover, the presence of pharmaceutical companies offering innovative anti-obesity treatments, particularly GLP-1 receptor agonists, is on the rise. As cultural attitudes evolve and medical tourism becomes more prevalent, especially in countries like the UAE and South Africa, the anti-obesity drug market is expected to continue its upward trajectory.
Strategic Insights
Market Segmentation Analysis
- By Type: The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.
- By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.
- By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominated in 2024.
- By GLP-1 Agonist: Further divided into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide being the most prominent in 2024.
- By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading the market.
- By Route of Administration: The market is segmented into Oral and Parenteral, with Oral being the most common route in 2024.
- By Distribution Channel: Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share.
Obesity is influenced by genetic, environmental, and lifestyle factors. Recent advancements indicate that individuals respond differently to anti-obesity medications based on their genetic profiles, metabolic rates, gut microbiota, and existing health conditions. This variability means that a medication effective for one patient may not work for another. Precision medicine is emerging in obesity treatment, utilizing pharmacogenomic testing and detailed patient profiling to identify the most effective drug or combination of drugs for each individual. Companies are developing diagnostic tools to analyze genetic markers related to obesity and drug metabolism, aiding clinicians in predicting patient responses to various treatments. The expanding pipeline of anti-obesity drugs targeting different mechanisms allows for tailored therapies that align with individual patient needs. For instance, if a patient does not respond well to a GLP-1 agonist, a physician may consider switching to or combining it with another agent targeting a different pathway.
Pharmacogenomic companies like Acosta and Phenomix are providing tests that support personalized obesity treatment, a trend expected to accelerate as more data and drugs become available. This shift towards individualized treatment regimens is anticipated to enhance the effectiveness, cost-efficiency, and acceptance of anti-obesity pharmacotherapy among patients and healthcare providers. In March 2025, VIVUS LLC launched QSYMIA® (phentermine and topiramate extended-release capsules) in the UAE, marking a significant step in addressing the region's rising obesity rates, projected to affect over 7.5 million people by 2035.
Country Insights
The market is further segmented by country, with Saudi Arabia holding the largest share in 2024. The prevalence of overweight and obesity in Saudi Arabia has nearly doubled over the past fifty years, with over half the population classified as overweight and more than 20% as obese. The economic burden of obesity management in the country is estimated at US$ 6.4 billion, underscoring the urgent need for effective interventions. The Saudi government has implemented various policies under its Vision 2030 plan to promote a healthier population.
In April 2025, Novo Nordisk signed a Memorandum of Understanding with Lifera to localize the manufacturing of semaglutide-based GLP-1 treatments in Saudi Arabia, enhancing the country's healthcare infrastructure. This agreement aims to launch Wegovy in Saudi Arabia, making it accessible to patients in both public and private sectors, reflecting the country's commitment to tackling obesity.
Company Profiles
Key players in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are pursuing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Anti-Obesity Drugs Market Forecast and Analysis
7. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 Middle East & Africa
14.1.1 Middle East & Africa Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Middle East & Africa Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.1.2.2.5 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.3.4.4.5 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.4.5.5.5 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
6.1 Middle East & Africa Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Anti-Obesity Drugs Market Forecast and Analysis
7. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 Middle East & Africa
14.1.1 Middle East & Africa Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 Middle East & Africa Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.1.2.2.5 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 South Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.3.4.4.5 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
14.4.5.5 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Type
14.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Drug Class
14.4.5.5.4 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.4.5.5.5 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Application
14.4.5.5.6 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Route Of Administration
14.4.5.5.7 Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
LIST OF TABLES
Table 1. Middle East & Africa Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 37. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. Heat Map Analysis by Key Players
Table 1. Middle East & Africa Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 34. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 35. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 36. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 37. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 38. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 39. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 40. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Middle East & Africa Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Middle East & Africa Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Mechanism of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Middle East & Africa Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. Company Positioning & Concentration
Figure 1. Middle East & Africa Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Anti-Obesity Drugs Market
Figure 4. Middle East & Africa Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East & Africa Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Mechanism of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Middle East & Africa Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. Middle East & Africa Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Saudi Arabia: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. South Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. United Arab Emirates: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Rest of Middle East & Africa: Middle East & Africa Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 40. Company Positioning & Concentration
